Core Viewpoint - The article discusses a class action lawsuit against Tempus AI, Inc. due to allegations of misleading statements and inflated financial metrics during a specified class period, leading to significant stock price decline [1][2][4]. Summary by Relevant Sections Class Action Details - Investors who purchased Tempus common stock between August 6, 2024, and May 27, 2025, are reminded of the August 12, 2025, deadline to file a lead plaintiff motion [1][5]. - The lawsuit claims that the defendants made materially false and misleading statements about the company's business and operations [4]. Allegations Against Tempus - A report by Spruce Point Capital on May 28, 2025, alleged that Tempus overstated its AI capabilities and revealed weaknesses in its financial guidance [2]. - Following this report, Tempus' stock price dropped by $12.67, or 19.2%, closing at $53.20 per share [3]. Specific Misconduct Allegations - The complaint outlines several key issues: 1. Inflated value of contract agreements, including non-binding opt-ins and self-funded contracts [4]. 2. Risk to the credibility of a joint venture with SoftBank, suggesting potential "round-tripping" of capital [4]. 3. Ambry's business model involved aggressive billing practices that could face scrutiny [4]. 4. AstraZeneca's reduced financial commitments through a questionable payment structure [4]. 5. Overall, these issues indicated weaknesses in Tempus' core operations and revenue prospects [4].

Core Viewpoint - Tempus AI, Inc. is facing a securities class action lawsuit for failing to disclose material information during the class period, which has led to a significant drop in its stock price [3][5]. Group 1: Lawsuit Details - Investors have until August 12, 2025, to file lead plaintiff applications if they purchased shares between August 6, 2024, and May 27, 2025 [1]. - The lawsuit is pending in the United States District Court for the Northern District of Illinois [1]. - The case is identified as Shouse v. Tempus AI, Inc., et al., No. 25-cv-06534 [5]. Group 2: Allegations Against Tempus - Tempus and its executives are accused of violating federal securities laws by not disclosing critical information during the class period [3]. - Spruce Point Capital Management reported several issues, including overstated AI capabilities, a history of executives cashing out before losses, and aggressive accounting practices [4]. - Concerns were raised regarding the AstraZeneca and Pathos AI deal, as well as a recent revision in financial guidance indicating weaknesses in core operations [4]. Group 3: Market Reaction - Following the news of the lawsuit and allegations, Tempus' share price fell by $12.67, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [5].